{
    "root": "185bba8c-5048-4e2f-8b98-97537c04a982",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "POTELIGEO",
    "value": "20250506",
    "ingredients": [
        {
            "name": "mogamulizumab",
            "code": "YI437801BE"
        },
        {
            "name": "citric acid monohydrate",
            "code": "2968PHW8QP"
        },
        {
            "name": "glycine",
            "code": "TE7660XO1C"
        },
        {
            "name": "polysorbate 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB"
        },
        {
            "name": "water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or SÃ©zary syndrome (SS) after at least one prior systemic therapy.",
    "contraindications": "1 mg/kg as an intravenous infusion over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle and on days 1 and 15 of each subsequent cycle ( 2 ).",
    "warningsAndPrecautions": "POTELIGEO (mogamulizumab-kpkc) injection is a sterile, preservative-free, clear to slightly opalescent colorless solution supplied in a carton containing one 20 mg/5 mL (4 mg/mL), single-dose glass vial (NDC 42747-761-01).",
    "adverseReactions": "None."
}